Author name: Leonardo Arias

For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the Abiomed business.

The company says it will use the money to develop AI agents and deepen its relationships with its 30 health technology partners.

While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.

The takeover adds high-growth, high-margin products to Steris’ portfolio, analysts said.

Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments.

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now “less likely.”

The lawsuit isn’t a surprise, after Alignment told investors it would take all available actions to improve its quality scores.

Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.

After Pfizer’s venture arm co-led Enodia Therapeutics’ $25 million seed round in January, the pharma has signed up to collaborate with the biotech on small-molecule drugs to eliminate pathogenic proteins where they’re being made.

Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.